Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sha Fu"'
Autor:
Li-Na He, Haifeng Li, Wei Du, Sha Fu, Linfeng luo, Tao Chen, Xuanye Zhang, Chen Chen, Yongluo Jiang, Yixing Wang, Yuhong Wang, Hui Yu, Yixin Zhou, Zuan Lin, Yuanyuan Zhao, Yan Huang, Hongyun Zhao, Wenfeng Fang, Yunpeng Yang, Li Zhang, Shaodong Hong
Publikováno v:
iScience, Vol 26, Iss 7, Pp 107058- (2023)
Summary: The immune and stromal contexture within the tumor microenvironment (TME) interact with cancer cells and jointly determine disease process and therapeutic response. We aimed at developing a risk scoring model based on TME-related genes of sq
Externí odkaz:
https://doaj.org/article/9435e0cd9f3d4bc2850761808524bced
Autor:
Liang Zeng, Shu-Hua Li, Shuo-Yu Xu, Kai Chen, Liang-Jun Qin, Xiao-Yun Liu, Fang Wang, Sha Fu, Ling Deng, Feng-Hua Wang, Lei Miao, Le Li, Na Liu, Ran Wang, Hai-Yun Wang
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundInfiltrating immune cells have been reported as prognostic markers in many cancer types. We aimed to evaluate the prognostic role of tumor-infiltrating lymphocytes, namely CD3+ T cells, CD8+ cytotoxic T cells and memory T cells (CD45RO+), i
Externí odkaz:
https://doaj.org/article/e5455f807ffc4c44bbdba1f8942cf90f
Autor:
Linfeng Luo, Anlin Li, Sha Fu, Wei Du, Li-Na He, Xuanye Zhang, Yixing Wang, Yixin Zhou, Yang Yunpeng, Zhang Li, Shaodong Hong
Publikováno v:
Immunologic Research. 71:213-228
Non-small-cell lung cancer (NSCLC) remains the major cause of cancer-related death. Immune checkpoint inhibition has become the cornerstone treatment for NSCLC. Cuproptosis is a newly identified form of cell death relying on mitochondrial respiration
Autor:
Yixing Wang, Sha Fu, Xuanye Zhang, Wei Du, Linfeng Luo, Yongluo Jiang, Yixin Zhou, Yuanyuan Zhao, Yunpeng Yang, Hongyun Zhao, Wenfeng Fang, Yan Huang, Li Zhang, Shaodong Hong
Publikováno v:
Frontiers in Immunology. 14
ObjectiveFew data are available on the optimal treatment options after disease progression from first-line treatment of immune checkpoint inhibitors (ICIs) plus chemotherapy. This study aimed to describe the safety and efficacy of continuing ICIs bey
Autor:
Xuanye Zhang, Yixin Zhou, Hualin Chen, Chen Chen, Zuan Lin, Li-na He, Wei Du, Tao Chen, Shaodong Hong, Sha Fu
Publikováno v:
Frontiers in immunology. 13
BackgroundPulmonary lymphoepithelioma-like carcinoma (PLELC) is a distinctive subtype of non-small cell lung carcinoma that was not well presented in clinical studies. The management of advanced PLELC remains an important, unmet need due to the pauci
Autor:
Liang Zeng, Hui Xu, Shu-Hua Li, Shuo-Yu Xu, Kai Chen, Liang-Jun Qin, Lei Miao, Fang Wang, Ling Deng, Feng-Hua Wang, Le Li, Sha Fu, Na Liu, Ran Wang, Ying-Qing Li, Hai-Yun Wang
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e005980
BackgroundNeuroblastoma (NB) places a substantial health burden on families worldwide. This study aimed to develop an immune checkpoint-based signature (ICS) based on the expression of immune checkpoints to better assess patient survival risk and pot
Autor:
Xuanye Zhang, Liangping Xia, Bei Zhang, Ping Chen, Shaodong Hong, Li-na He, Chen Chen, Yixin Zhou, Hui Yu, Sha Fu
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Anti-PD-1)/programmed cell death-ligand 1 (PD-L1) antibody plus platinum-based chemotherapy (PBC) has replaced PBC as first-line treatment for patients with non-squamous (sq) non-small cell lung cancer (NSCLC) lacking targetable driver mutations. How
Autor:
Wenfeng Fang, Xuanye Zhang, Hongyun Zhao, Xue Hou, Yan Huang, Chen Chen, Yuxiang Ma, Li Zhang, Yunpeng Yang, Yixin Zhou, Cong Xue, Shaodong Hong, Sha Fu
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-11 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-11 (2018)
Background Immune-checkpoint inhibitors plus chemotherapy are emerging as effective first-line treatment in advanced non-small-cell lung carcinoma (NSCLC), but little is known about the magnitude of benefits and potential clinical predictors. Methods
Autor:
Ying Tang, Sha Fu, Hui Y. Lan, Peifen Liang, Junzhe Chen, Anping Xu, Min Feng, Bo Liu, Ben Lee, Baojuan Lin
Publikováno v:
Immunity & Ageing : I & A
Immunity & Ageing, Vol 15, Iss 1, Pp 1-8 (2018)
Immunity & Ageing, Vol 15, Iss 1, Pp 1-8 (2018)
Background Recent studies show that C-reactive protein (CRP) is not only a biomarker but also a pathogenic mediator contributing to the development of inflammation and ageing-related diseases. However, serum levels of CRP in the healthy ageing popula
Autor:
Haowen Zhong, Ya Liu, Zhenjian Xu, Peifeng Liang, Hui Yang, Xiao Zhang, Jun Zhao, Junzhen Chen, Sha Fu, Ying Tang, Jun Lv, Julie Wang, Nancy Olsen, Anping Xu, Song Guo Zheng
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 9 (2018)
Frontiers in Immunology, Vol 9 (2018)
Lupus nephritis is one of most severe complications of systemic erythematosus lupus and current approaches are not curative for lupus nephritis. Although CD4+Foxp3+ regulatory T cells (Treg) are crucial for prevention of autoimmunity, the therapeutic